Luye Pharma Converts $25 Million of Tranche A Bonds
Luye Pharma Group Ltd. has converted US$25 million of its Tranche A Bonds at a conversion price of HK$3.672 per share. This is part of a broader financial strategy involving US$100 million in convertible bonds due in 2025, potentially affecting its financial structure and investor relations. The latest analyst rating for Luye Pharma (HK:2186) is a Buy, with a price target of HK$5.00. Luye Pharma focuses on innovative pharmaceutical products, primarily in the Chinese market, and has a current market cap of HK$14.49 billion.
Luye Pharma Group ( (HK:2186) ) has shared an update.
Luye Pharma Group Ltd. announced the conversion of US$25,000,000 of its Tranche A Bonds at a conversion price of HK$3.672 per share. This move is part of the company’s ongoing financial strategy involving US$100,000,000 5.85% convertible bonds due in 2025, which may impact its financial structure and investor relations.
The most recent analyst rating on (HK:2186) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company incorporated in Bermuda, primarily engaged in the development, production, and sale of innovative pharmaceutical products. The company focuses on the global market, with a particular emphasis on the Chinese market.
Average Trading Volume: 106,358,790
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.49B
